SYSTEM GENERATING A CONSTRAINT FIELD, AND MEDICAL DEVICE IMPLEMENTING THE SAME

• US 20160143859A1
• Filed: 07/11/2014
• Published: 05/26/2016
• Est. Priority Date: 07/12/2013
• Status: Active Grant

• Current Assignee: Cell Constraint & Cancer Co.
• Original Assignee: Cell Constraint & Cancer Co.
• Inventors: Brossel, Remy
• Granted Patent: US 10,449,160 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• CPC Class Codes: A61K 9/5094 Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• CPC Class Codes: A61K 9/5115 Inorganic compounds
• CPC Class Codes: A61N 1/406 using implantable thermoseeds or injected particles for localized hyperthermia preparations of seeds and particles A61K41/0052
• CPC Class Codes: A61N 2/004 specially adapted for a specific therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Disclosed is a system including (1) an injection device including injectable magnetizable nanoparticles and a component for injecting the same, and (2) a unit for applying a constraint physically and/or mechanically to a tumor associated to an neoangiogenic network where, after having been injected, the particles are retained. Also disclosed is a method for treating tumors, especially tumors associated with a neoangiogenic network, including the steps of: injecting a composition including magnetizable nanoparticles; optionally performing imaging using an imaging device to detect a concentration of nanoparticles retained in the neoangiogenic network; and applying a contact-free constraint onto a tumor in vivo, by a gradient of magnetic field and the application being directed to the tumor region.

Claims

1. Medical system comprising (1) injectable magnetizable nanoparticles and means for injecting the same, and (2) means for applying a physical and/or mechanical constraint to a tumor associated to a neoangiogenic network where, after having been injected, the particles are retained, said means for applying a physical and/or mechanical constraint being a generator releasing a gradient of magnetic field;

and

wherein

the system is neither a cell construct nor an implant;

the system is not used for treating a tumor by pharmaceutical means;

the particles are not used such as drug carrier or as imaging agent.

2. Medical system according to claim 1,

wherein the nanoparticles are composed of iron oxide.

3. Medical system according to claim 1, wherein said nanoparticles are coated with a non-pharmaceutical composition.

4. Medical system according to claim 1, wherein said nanoparticles have a mean diameter ranging from 30 to 1000 nm.

5. Medical system according to claim 1, wherein the nanoparticles are suspended in a colloidal or non-colloidal vehicle.

13. The Medical system according to claim 2, wherein the nanoparticles comprise magnetite (Fe3O4), maghemite ([gamma]-Fe2O3), ferumoxides or mixtures thereof.

14. Medical system according to claim 2, wherein said nanoparticles are coated with a non-pharmaceutical composition.

15. Medical system according to claim 2, wherein said nanoparticles have a mean diameter ranging from 30 to 1000 nm.

16. Medical system according to claim 3, wherein said nanoparticles have a mean diameter ranging from 30 to 1000 nm.

17. Medical system according to claim 2, wherein the nanoparticles are suspended in a colloidal or non-colloidal vehicle.

18. Medical system according to claim 3, wherein the nanoparticles are suspended in a colloidal or non-colloidal vehicle.

19. Medical system according to claim 4, wherein the nanoparticles are suspended in a colloidal or non-colloidal vehicle.

6. A method for treating tumors by physical and/or mechanical means, comprising the steps of:

injecting a composition containing nanoparticles; and

applying physical and/or mechanical means for applying a contact-free constraint onto a tumor in vivo, said physical and/or mechanical means being a gradient of magnetic field and the application being directed to the tumor region;

and wherein the method for treating tumors is not a pharmaceutical method.

7. Method according to claim 6, wherein the amount of injected nanoparticles ranges from 100 μ

g to 10 g.

8. Method according to claim 6, wherein at least 25-60% of the injected particles are retained in the tumor neoangiogenic network.

9. Method according to claim 6, wherein the tumor is a malignant epithelial tumor.

10. Method according to claim 6, wherein the tumor is a pancreas cancer tumor, or a breast cancer tumor.

20. Method according to claim 6, wherein at least 25-600 of the injected particles are retained in the tumor neoangiogenic network.

11. Method for modifying the cancerous phenotype of cancer cells to normal cells in a tumor region, the method comprising the steps of:

injecting a composition containing the nanoparticles as described above, such that the nanoparticles are retained by the neoangiogenic network surrounding the tumor; and

implementing physical and/or mechanical means for applying a contact-free constraint onto the tumor cells, this means comprising or consisting of a gradient of magnetic field applied on the nanoparticles, in vivo, from an outside source of gradient of magnetic field;

and wherein the method for modifying the cancerous phenotype of cancer cells is not a pharmaceutical method.

12. Method according to claim 11, wherein the modified cancer phenotype relates to the reduction of tumor volume and/or surfaces of the tumor cells.